Cordatus Wealth Management’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$351K Buy
1,779
+95
+6% +$18.3K 0.08% 128
2025
Q4
$310K Sell
1,684
-175
-9% -$30.7K 0.07% 138
2025
Q3
$285K Buy
1,859
+39
+2% +$5.9K 0.07% 140
2025
Q2
$254K Sell
1,820
-73
-4% -$10.2K 0.06% 151
2025
Q1
$278K Buy
1,893
+332
+21% +$48K 0.08% 134
2024
Q4
$205K Buy
+1,561
New +$219K 0.05% 143
2023
Q3
Sell
-3,298
Closed -$472K 71
2023
Q2
$472K Buy
+3,298
New +$485K 0.18% 98
2022
Q3
Sell
-5,119
Closed -$676K 73
2022
Q2
$676K Buy
+5,119
New +$672K 0.32% 102

Other funds holding AZN

Cordatus Wealth Management's AZN Position: Q1 2026 in Review

Cordatus Wealth Management increased its AstraZeneca (AZN) stake by 5.6% in Q1 2026, buying an estimated $18.3K and bringing the position to 1,779 shares worth $351K. The position accounts for 0.08% of the portfolio, ranked #128.

Cordatus Wealth Management first reported a position in AZN in Q2 2022 and has held it in 8 quarters since. The position peaked at $676K in Q2 2022. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Cordatus Wealth Management held 1,779 shares of AstraZeneca worth $351K as of Q1 2026.
  • Cordatus Wealth Management bought 95 AstraZeneca shares in Q1 2026, an estimated $18.3K.
  • AstraZeneca made up 0.08% of Cordatus Wealth Management's portfolio in Q1 2026, its #128 holding.
  • Cordatus Wealth Management first reported a position in AstraZeneca in Q2 2022 and has held it in 8 quarters since.
  • Cordatus Wealth Management's AstraZeneca position peaked at $676K in Q2 2022.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Cordatus Wealth Management's 13F filing for Q1 2026, filed 29 Apr 2026.